Impact of Fontan Fenestration on Adverse Cardiovascular Outcomes: A Multicentre Study

Nabil Dib1, Michelle Samuel1, Sylvie Levesque2

  • 1Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada.

PubMed

Insights

Fenestrating a Fontan baffle did not increase long-term adverse cardiovascular events in patients with univentricular hearts. Further research is needed to fully understand potential risks of open fenestrations, such as arrhythmias.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease
  • Cardiac Surgery

Background:

  • Fenestrating a Fontan baffle is linked to better short-term outcomes in univentricular hearts.
  • Long-term effects of fenestrated Fontan baffles are not well understood.
  • Adverse cardiovascular events are a concern for patients with Fontan circulation.

Purpose of the Study:

  • To evaluate the long-term impact of fenestrated Fontan baffles on adverse cardiovascular events.
  • To assess risks including mortality, transplantation, arrhythmias, and thromboemboli.
  • To clarify the safety profile of fenestrated Fontan baffles.

Main Methods:

  • Retrospective cohort study of 407 patients with total cavopulmonary connection.
  • Comparison of patients with and without Fontan baffle fenestration.
  • Independent adjudication of outcomes and consideration of confounders and competing risks.

Main Results:

  • Fenestration closure occurred in 79.9% of patients within 2 years.
  • Open fenestration was not associated with increased risk of major adverse cardiovascular events (HR 1.18, P=0.521).
  • No significant association found with mortality, transplantation, or arrhythmias, but sensitivity analyses suggested potential risks.

Conclusions:

  • This study found no significant long-term association between open Fontan baffle fenestration and major adverse cardiovascular events.
  • Further investigation is warranted regarding potential associations with atrial arrhythmias or thromboemboli.
  • The findings suggest fenestration is safe in the long term for Fontan patients.
Abstract